Abbott Laboratories (NYSE:ABT - Get Free Report) CFO Philip Boudreau acquired 2,200 shares of the firm's stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares of the company's stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Abbott Laboratories Trading Up 1.9%
Abbott Laboratories stock opened at $92.85 on Tuesday. The firm has a 50 day simple moving average of $105.56 and a 200-day simple moving average of $116.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The stock has a market capitalization of $161.71 billion, a PE ratio of 26.01, a price-to-earnings-growth ratio of 1.52 and a beta of 0.79. Abbott Laboratories has a 12-month low of $90.72 and a 12-month high of $139.06.
Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business's revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.
Abbott Laboratories Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.
Institutional Trading of Abbott Laboratories
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after purchasing an additional 162 shares during the period. United Bank boosted its position in shares of Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after buying an additional 2,001 shares during the period. Main Street Financial Solutions LLC boosted its position in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock worth $1,618,000 after buying an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its holdings in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after buying an additional 292,547 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Jefferies Financial Group decreased their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating for the company in a report on Friday, April 17th. Freedom Capital raised shares of Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 29th. Royal Bank Of Canada cut their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Argus cut their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Finally, Barclays cut their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $119.43.
Read Our Latest Report on Abbott Laboratories
About Abbott Laboratories
(
Get Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
